Restorative Dentistry and Endodontics

The Korean Academy of Conservative Dentistry (대한치과보존학회)
권호 표지
DOI QR코드

DOI QR Code

Dental care for patients taking antiresorptive drugs: a literature review

  • Song, Minju (Department of Conservative Dentistry, College of Dentistry, Dankook University)
  • Received : 2019.08.05
  • Accepted : 2019.10.09
  • Published : 2019.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Antiresorptive drugs (ARDs), such as bisphosphonates or denosumab, that prevent bone resorption are widely used in patients with osteoporosis or with cancer that has metastasized to the bones. Although osteonecrosis of the jaw (ONJ) is a well-documented complication of ARD use, the benefits ARDs outweigh the complication. Thus, research has focused on finding ways to prevent or reduce the risk of developing ONJ. Dentists, as part of a multi-professional team, have a critical role in preventing ONJ. However, many dentists tend to hesitate to provide dental care to patients with ONJ, or tend to think that it is a problem to be dealt with by oral surgeons. This review gives an overview of ARD-related ONJ and provides the guidelines for dental care in patients taking ARDs to lower the risk of developing ONJ.

Keywords

References

  1. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007;86:1013-1021. https://doi.org/10.1177/154405910708601101
  2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117. https://doi.org/10.1016/S0278-2391(03)00720-1
  3. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-1956. https://doi.org/10.1016/j.joms.2014.04.031
  4. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009;67:2-12.
  5. Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H; American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011;142:1243-1251. https://doi.org/10.14219/jada.archive.2011.0108
  6. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-34. https://doi.org/10.1186/bcr414
  7. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005;20:977-986. https://doi.org/10.1359/JBMR.050109
  8. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005;17:462-466. https://doi.org/10.1097/00002281-200507000-00013
  9. Brufsky AM. Zoledronic acid for cancer therapy--induced and postmenopausal bone loss. Expert Opin Pharmacother 2008;9:1013-1028. https://doi.org/10.1517/14656566.9.6.1013
  10. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS; American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-3736. https://doi.org/10.1200/JCO.2002.06.037
  11. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J; Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621. https://doi.org/10.1002/cncr.20308
  12. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106. https://doi.org/10.1016/S8756-3282(99)00116-7
  13. Bogado CE, Zanchetta MB, Boailchuk JA, Massari FE, Zanchetta JR. Denosumab: what's new? Curr Osteoporos Rep 2011;9:12-19. https://doi.org/10.1007/s11914-010-0040-1
  14. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100. https://doi.org/10.1210/edrv.19.1.0325
  15. Romas E. Clinical applications of RANK-ligand inhibition. Intern Med J 2009;39:110-116. https://doi.org/10.1111/j.1445-5994.2008.01732.x
  16. Geusens P. Emerging treatments for postmenopausal osteoporosis - focus on denosumab. Clin Interv Aging 2009;4:241-250. https://doi.org/10.2147/CIA.S3333
  17. Uyanne J, Calhoun CC, Le AD. Antiresorptive drug-related osteonecrosis of the jaw. Dent Clin North Am 2014;58:369-384. https://doi.org/10.1016/j.cden.2013.12.006
  18. Hao L, Chen W, McConnell M, Zhu Z, Li S, Reddy M, Eleazer PD, Wang M, Li YP. A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease. Infect Immun 2015;83:1235-1245. https://doi.org/10.1128/IAI.01713-14
  19. Mullard A. Merck &Co. drops osteoporosis drug odanacatib. Nat Rev Drug Discov 2016;15:669.
  20. Boquete-Castro A, Gomez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res 2016;27:367-375.
  21. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S; Japanese Allied Committee on Osteonecrosis of the Jaw. Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 2017;35:6-19. https://doi.org/10.1007/s00774-016-0810-7
  22. Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sandor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ. J Clin Densitom 2017;20:8-24. https://doi.org/10.1016/j.jocd.2016.09.005
  23. Nicolatou-Galitis O, Schiodt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van den Wyngaert T. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 2019;127:117-135. https://doi.org/10.1016/j.oooo.2018.09.008
  24. Khan A, Morrison A, Cheung A, Hashem W, Compston J. Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int 2016;27:853-859. https://doi.org/10.1007/s00198-015-3335-3
  25. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102. https://doi.org/10.1056/NEJM200507073530120
  26. Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007;18:2015-2019. https://doi.org/10.1093/annonc/mdm370
  27. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carriere P, Dansey R. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23:1341-1347. https://doi.org/10.1093/annonc/mdr435
  28. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27:5356-5362. https://doi.org/10.1200/JCO.2009.21.9584
  29. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-5139. https://doi.org/10.1200/JCO.2010.29.7101
  30. Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martin M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 2016;24:447-455. https://doi.org/10.1007/s00520-015-2904-5
  31. Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vescovi P, Manfredi M, Arduino PG, Broccoletti R, Musciotto A, Di Fede O, Lazarovici TS, Campisi G, Yarom N. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 2010;123:1060-1064. https://doi.org/10.1016/j.amjmed.2010.04.033
  32. Lodi G, Sardella A, Salis A, Demarosi F, Tarozzi M, Carrassi A. Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg 2010;68:107-110. https://doi.org/10.1016/j.joms.2009.07.068
  33. Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncol 2012;48:817-821. https://doi.org/10.1016/j.oraloncology.2012.03.009
  34. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423. https://doi.org/10.1016/j.joms.2006.10.061
  35. Otto S, Troltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, Ehrenfeld M, Pautke C. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 2015;43:847-854. https://doi.org/10.1016/j.jcms.2015.03.039
  36. Otto S, Hafner S, Mast G, Tischer T, Volkmer E, Schieker M, Sturzenbaum SR, von Tresckow E, Kolk A, Ehrenfeld M, Pautke C. Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle? J Oral Maxillofac Surg 2010;68:1158-1161. https://doi.org/10.1016/j.joms.2009.07.079
  37. Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, Bauss F, Ehrenfeld M, Schieker M. Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 2010;68:2837-2845. https://doi.org/10.1016/j.joms.2010.07.017
  38. Aguirre JI, Akhter MP, Kimmel DB, Pingel JE, Williams A, Jorgensen M, Kesavalu L, Wronski TJ. Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J Bone Miner Res 2012;27:2130-2143. https://doi.org/10.1002/jbmr.1669
  39. Song M, Alshaikh A, Kim T, Kim S, Dang M, Mehrazarin S, Shin KH, Kang M, Park NH, Kim RH. Preexisting periapical inflammatory condition exacerbates tooth extraction-induced bisphosphonate-related osteonecrosis of the jaw lesions in mice. J Endod 2016;42:1641-1646. https://doi.org/10.1016/j.joen.2016.07.020
  40. Kim T, Kim S, Song M, Lee C, Yagita H, Williams DW, Sung EC, Hong C, Shin KH, Kang MK, Park NH, Kim RH. Removal of pre-existing periodontal inflammatory condition before tooth extraction ameliorates medication-related osteonecrosis of the jaw-like lesion in mice. Am J Pathol 2018;188:2318-2327. https://doi.org/10.1016/j.ajpath.2018.06.019
  41. Ramirez L, Lopez-Pintor RM, Casanas E, Arriba L, Hernandez G. New non-bisphosphonate drugs that produce osteonecrosis of the jaws. Oral Health Prev Dent 2015;13:385-393.
  42. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sandor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30:3-23. https://doi.org/10.1002/jbmr.2405
  43. Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: clinical and practical guidelines. J Int Soc Prev Community Dent 2016;6:97-104. https://doi.org/10.4103/2231-0762.178742
  44. Karna H, Gonzalez J, Radia HS, Sedghizadeh PP, Enciso R. Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: a systematic review with meta-analyses. Oral Oncol 2018;85:15-23. https://doi.org/10.1016/j.oraloncology.2018.08.003
  45. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117-120. https://doi.org/10.1093/annonc/mdn554
  46. Mucke T, Deppe H, Hein J, Wolff KD, Mitchell DA, Kesting MR, Retz M, Gschwend JE, Thalgott M. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years. J Craniomaxillofac Surg 2016;44:1689-1693. https://doi.org/10.1016/j.jcms.2016.07.026
  47. Vandone AM, Donadio M, Mozzati M, Ardine M, Polimeni MA, Beatrice S, Ciuffreda L, Scoletta M. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 2012;23:193-200. https://doi.org/10.1093/annonc/mdr039
  48. Bramati A, Girelli S, Farina G, Dazzani MC, Torri V, Moretti A, Piva S, Dimaiuta M, La Verde N. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab 2015;33:119-124. https://doi.org/10.1007/s00774-014-0566-x
  49. Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol 2014;10:257-275. https://doi.org/10.2217/fon.13.211
  50. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-2410. https://doi.org/10.1016/j.joms.2007.08.003
  51. Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. J Clin Endocrinol Metab 2014;99:2729-2735. https://doi.org/10.1210/jc.2013-4119
  52. Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, Voinea-Griffin AE, CONDOR Collaborative GroupBeadnell S, Craig RG, DeRouen T, Desaranayake A, Gilbert A, Gilbert GH, Goldberg K, Hauley R, Hashimoto M, Holmes J, Latzke B, Leroux B, Lindblad A, Richman J, Safford M, Ship J, Thompson VP, Williams OD, Yin W. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 2011;90:439-444. https://doi.org/10.1177/0022034510397196
  53. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J; ESMO Guidelines Working Group. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2014;25(Supplement 3):iii124-iii137. https://doi.org/10.1093/annonc/mdu103
  54. McCloskey EV, Johansson H, Harvey NC, Compston J, Kanis JA. Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK-an analysis of anonymous website activity. Osteoporos Int 2017;28:71-76. https://doi.org/10.1007/s00198-016-3696-2
  55. Fedele S, Kumar N, Davies R, Fiske J, Greening S, Porter S. Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review. Oral Dis 2009;15:527-537. https://doi.org/10.1111/j.1601-0825.2009.01581.x
  56. Kim I, Ki H, Lee W, Kim H, Park JB. The effect of systemically administered bisphosphonates on bony healing after tooth extraction and osseointegration of dental implants in the rabbit maxilla. Int J Oral Maxillofac Implants 2013;28:1194-1200. https://doi.org/10.11607/jomi.2685
  57. Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, Van Poznak CH. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2017;35:2062-2081. https://doi.org/10.1200/JCO.2016.70.7257
  58. Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, Nkenke E. Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig 2010;14:311-317. https://doi.org/10.1007/s00784-009-0293-1
  59. Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:249-258. https://doi.org/10.1016/j.tripleo.2007.01.040
  60. Kang B, Cheong S, Chaichanasakul T, Bezouglaia O, Atti E, Dry SM, Pirih FQ, Aghaloo TL, Tetradis S. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J Bone Miner Res 2013;28:1631-1640. https://doi.org/10.1002/jbmr.1894
  61. Ferraz CC, Gomes NV, Gomes BP, Zaia AA, Teixeira FB, Souza-Filho FJ. Apical extrusion of debris and irrigants using two hand and three engine-driven instrumentation techniques. Int Endod J 2001;34:354-358. https://doi.org/10.1046/j.1365-2591.2001.00394.x
  62. Gallego L, Junquera L, Pelaz A, Diaz-Bobes C. Rubber dam clamp trauma during endodontic treatment: a risk factor of bisphosphonate-related osteonecrosis of the jaw? J Oral Maxillofac Surg 2011;69:e93-e95.
  63. Moinzadeh AT, Shemesh H, Neirynck NA, Aubert C, Wesselink PR. Bisphosphonates and their clinical implications in endodontic therapy. Int Endod J 2013;46:391-398. https://doi.org/10.1111/iej.12018
  64. AlRahabi MK, Ghabbani HM. Clinical impact of bisphosphonates in root canal therapy. Saudi Med J 2018;39:232-238. https://doi.org/10.15537/smj.2018.3.20923
  65. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575. https://doi.org/10.1016/j.joms.2005.07.010
  66. Poubel VL, Silva CA, Mezzomo LA, De Luca Canto G, Rivero ER. The risk of osteonecrosis on alveolar healing after tooth extraction and systemic administration of antiresorptive drugs in rodents: a systematic review. J Craniomaxillofac Surg 2018;46:245-256. https://doi.org/10.1016/j.jcms.2017.11.008
  67. Borromeo GL, Tsao CE, Darby IB, Ebeling PR. A review of the clinical implications of bisphosphonates in dentistry. Aust Dent J 2011;56:2-9.
  68. Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G, Ferronato G, Nocini PF, Bedogni A. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg 2010;68:797-804. https://doi.org/10.1016/j.joms.2009.10.026
  69. Kwon YD, Ohe JY, Kim DY, Chung DJ, Park YD. Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? Clin Oral Implants Res 2011;22:100-105. https://doi.org/10.1111/j.1600-0501.2010.01965.x
  70. Lee CY, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study. Implant Dent 2010;19:29-38. https://doi.org/10.1097/ID.0b013e3181cec8bc
  71. Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:1167-1173. https://doi.org/10.1016/j.joms.2009.02.004
  72. O'Connell JE, Ikeagwani O, Kearns GJ. A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery? Ir J Med Sci 2012;181:237-242. https://doi.org/10.1007/s11845-011-0790-5
  73. Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab 2015;22:151-165. https://doi.org/10.11005/jbm.2015.22.4.151
  74. Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M, Kondou E, Takeda D, Kojima Y, Sato S, Yanamoto S, Komatsubara H, Umeda M, Kirita T, Kurita H, Shibuya Y, Komori T; Japanese Study Group of Cooperative Dentistry with Medicine (JCDM). A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int 2017;28:2465-2473. https://doi.org/10.1007/s00198-017-4063-7
  75. de Molon RS, Shimamoto H, Bezouglaia O, Pirih FQ, Dry SM, Kostenuik P, Boyce RW, Dwyer D, Aghaloo TL, Tetradis S. OPG-Fc but not zoledronic acid discontinuation reverses osteonecrosis of the jaws (ONJ) in mice. J Bone Miner Res 2015;30:1627-1640. https://doi.org/10.1002/jbmr.2490
  76. Ohga N, Yamazaki Y, Tsuboi K, Kitagawa Y. Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: a case report and hypothesis. Quintessence Int 2015;46:621-626. https://doi.org/10.3290/j.qi.a33528
  77. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, Nakayama T, Bessho K. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg 2012;41:1397-1403. https://doi.org/10.1016/j.ijom.2012.06.020
  78. Tsao C, Darby I, Ebeling PR, Walsh K, O'Brien-Simpson N, Reynolds E, Borromeo G. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 2013;71:1360-1366. https://doi.org/10.1016/j.joms.2013.02.016
  79. Allen MR. Medication-related osteonecrosis of the jaw: basic and translational science updates. Oral Maxillofac Surg Clin North Am 2015;27:497-508. https://doi.org/10.1016/j.coms.2015.06.002
  80. Hikita H, Miyazawa K, Tabuchi M, Kimura M, Goto S. Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. J Bone Miner Metab 2009;27:663-672. https://doi.org/10.1007/s00774-009-0090-6
  81. Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, Kousteni S, Raghavan S. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci 2011;1218:62-79. https://doi.org/10.1111/j.1749-6632.2010.05835.x
  82. Ravosa MJ, Ning J, Liu Y, Stack MS. Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts. Arch Oral Biol 2011;56:491-498. https://doi.org/10.1016/j.archoralbio.2010.11.003
  83. Pabst AM, Ziebart T, Koch FP, Taylor KY, Al-Nawas B, Walter C. The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study. Clin Oral Investig 2012;16:87-93. https://doi.org/10.1007/s00784-010-0507-6
  84. Yamashita J, Koi K, Yang DY, McCauley LK. Effect of zoledronate on oral wound healing in rats. Clin Cancer Res 2011;17:1405-1414. https://doi.org/10.1158/1078-0432.CCR-10-1614
  85. Allam E, Allen M, Chu TM, Ghoneima A, Jack Windsor L. In vivo effects of zoledronic acid on oral mucosal epithelial cells. Oral Dis 2011;17:291-297. https://doi.org/10.1111/j.1601-0825.2010.01739.x
  86. Iwamatsu-Kobayashi Y, Satoh-Kuriwada S, Yamamoto T, Hirata M, Toyoda J, Endo H, Kindaichi K, Komatsu M. A case of multiple idiopathic external root resorption: a 6-year follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:772-779. https://doi.org/10.1016/j.tripleo.2004.11.047
  87. Patel S, Saberi N. External cervical resorption associated with the use of bisphosphonates: a case series. J Endod 2015;41:742-748. https://doi.org/10.1016/j.joen.2015.01.035
  88. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005;139:101-111. https://doi.org/10.1111/j.1365-2249.2005.02665.x
  89. Makkonen N, Salminen A, Rogers MJ, Frith JC, Urtti A, Azhayeva E, Monkkonen J. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci 1999;8:109-118. https://doi.org/10.1016/S0928-0987(98)00065-7
  90. Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 2003;23:649-654. https://doi.org/10.1089/107999003322558782
  91. Deeb JG, Azarnoush K, Laskin DM, Deeb GR. Discontinuation of denosumab as a potential cause of generalized external cervical root resorption: a case report. J Endod 2019;45:640-644. https://doi.org/10.1016/j.joen.2019.02.013
  92. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011;26:530-537. https://doi.org/10.1002/jbmr.251
  93. Hsiao A, Glickman G, He J. A retrospective clinical and radiographic study on healing of periradicular lesions in patients taking oral bisphosphonates. J Endod 2009;35:1525-1528. https://doi.org/10.1016/j.joen.2009.07.020
  94. Dereci O, Orhan EO, Irmak O, Ay S. The effect of the duration of intravenous zolendronate medication on the success of non-surgical endodontic therapy: a retrospective study. BMC Oral Health 2016;16:9. https://doi.org/10.1186/s12903-016-0163-6
  95. Knight RJ, Reddy C, Rtshiladze MA, Lvoff G, Sherring D, Marucci D. Bisphosphonate-related osteonecrosis of the jaw: tip of the iceberg. J Craniofac Surg 2010;21:25-32. https://doi.org/10.1097/SCS.0b013e3181c347a0

Cited by

  1. A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers vol.12, pp.5, 2019, https://doi.org/10.3390/cancers12051209
  2. Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies vol.11, pp.11, 2019, https://doi.org/10.3390/app11114865